Intravenous administration of tissue plasminogen activator immediately after the injection of numerous small blood clots into the carotid circulation in rabbit embolic stroke model animals caused a significant reduction in neurological damage. In vitro studies indicate that tissue plasminogen activator produced substantial lysis of clots at concentrations comparable to those expected in vivo, suggesting that this may be the mechanism of action of this drug. Drug-induced hemorrhages were not demonstrable. Tissue plasminogen activator may be of value for the immediate treatment of embolic stroke
Animal models of acute ischemic stroke have been criticized for failing to translate to human stroke...
The online version of this article, along with updated information and services, is located on th
Der Schlaganfall ist die häufigste neurologische Erkrankung und mit 12 % aller Todesfälle die dritth...
We studied thrombolysis in an animal model of embolic stroke to determine the safety of tissue plasm...
Thrombolysis with tissue plasminogen activator (tPA) has been used to treat myocardial infarction an...
Fibrinolytic therapy for acute cerebral embolism remains controversial. A major reason for the contr...
Fibrinolytic therapy for acute cerebral embolism remains controversial. A major reason for the contr...
We describe a model of thromboembolic stroke in rabbits that utilizes the Seldinger technique and di...
Fibrinolytic therapy for acute cerebral embolism remains controversial. A major reason for the contr...
Early fibrinolytic therapy with full molecular tissue plasminogen activator (t-PA) has been observed...
Fibrinolytic therapy may be effective in the treatment of ischemic stroke, and clinical trials are u...
Background and Purpose We compared the activity of a new long-half-life, fibrin-specific tissue-type...
Background and Purpose—It has been proposed that spin trap agents such as N-t-butyl-phenylnitrone (P...
Background and Purpose—Early reperfusion using tissue-type plasminogen activator is the only therape...
Recombinant tissue plasminogen activator (rtPA) is the only effective drug approved by US FDA to tre...
Animal models of acute ischemic stroke have been criticized for failing to translate to human stroke...
The online version of this article, along with updated information and services, is located on th
Der Schlaganfall ist die häufigste neurologische Erkrankung und mit 12 % aller Todesfälle die dritth...
We studied thrombolysis in an animal model of embolic stroke to determine the safety of tissue plasm...
Thrombolysis with tissue plasminogen activator (tPA) has been used to treat myocardial infarction an...
Fibrinolytic therapy for acute cerebral embolism remains controversial. A major reason for the contr...
Fibrinolytic therapy for acute cerebral embolism remains controversial. A major reason for the contr...
We describe a model of thromboembolic stroke in rabbits that utilizes the Seldinger technique and di...
Fibrinolytic therapy for acute cerebral embolism remains controversial. A major reason for the contr...
Early fibrinolytic therapy with full molecular tissue plasminogen activator (t-PA) has been observed...
Fibrinolytic therapy may be effective in the treatment of ischemic stroke, and clinical trials are u...
Background and Purpose We compared the activity of a new long-half-life, fibrin-specific tissue-type...
Background and Purpose—It has been proposed that spin trap agents such as N-t-butyl-phenylnitrone (P...
Background and Purpose—Early reperfusion using tissue-type plasminogen activator is the only therape...
Recombinant tissue plasminogen activator (rtPA) is the only effective drug approved by US FDA to tre...
Animal models of acute ischemic stroke have been criticized for failing to translate to human stroke...
The online version of this article, along with updated information and services, is located on th
Der Schlaganfall ist die häufigste neurologische Erkrankung und mit 12 % aller Todesfälle die dritth...